

**THIS PAGE IS INSERTED BY OIPE SCANNING
AND IS NOT PART OF THE OFFICIAL RECORD**

Best Available Images

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

BLACK BORDERS

TEXT CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT

BLURRY OR ILLEGIBLE TEXT

SKewed/SLANTED IMAGES

COLORED PHOTOS HAVE BEEN RENDERED INTO BLACK AND WHITE

VERY DARK BLACK AND WHITE PHOTOS

UNDECIPHERABLE GRAY SCALE DOCUMENTS

**IMAGES ARE THE BEST AVAILABLE
COPY. AS RESCANNING *WILL NOT*
CORRECT IMAGES, PLEASE DO NOT
REPORT THE IMAGES TO THE
PROBLEM IMAGE BOX.**

ECCO 10

Abstract form

Wwe 12-16 87
(Office use only)

It is essential that the abstract conforms to the guidelines. See sample abstract on the next page.

ECTEINASCIDON (ET-743) IN HEAVILY PRETREATED REFRACTORY SARCOMAS: PRELIMINARY EVIDENCE OF ACTIVITY

S. Delaloge¹, M. Riofrio¹, E. Brain², P. Cottu³, A. Taamma⁴, M. Marty³, C. Guzman⁵, J.L. Misser¹, E. Cvitkovic⁴, ¹Hop Paul Brousse; ²Centre René Huguenin; ³Hop St Louis; ⁴CAC, France; ⁵Pharmamar, Spain.

ET-743 is a tetrahydro-isoquinolone of marine origin, currently in late phase I, early phase II development, with neutropenia (N) and thrombocytopenia (T) as limiting toxicities. Fatigue and reversible transaminitis (Tm) were also noticed. Antitumoral activity has been detected during the 24 hours continuous infusion (CI)-every 3 weeks schedule phase I (ASCO 1999, abst 680), which has completed accrual. We report here our current overall experience in treatment-refractory advanced sarcoma patients (pts). Pts charact: Eleven pts (9 soft tissue sarcomas (STS) and 2 osteosarcomas (OS)) received ET-743, 10 at the recommended dose (1500 µg/m²), one at the maximum tolerated dose (1800 µg/m²). 9 of them were treated in the phase I trial, while 2 received ET-743 on a compassionate use basis. Sex: 6 men/5 women, median age: 37 years (16-71), median number of previous chemotherapy regimens: 2 (1-4) (all pts pre-treated with anthracyclines and alkylators); median PS: 1 (0-2), median number of metastatic sites 2 (1-3). Results: Toxicity is evaluable for the 38 given cycles. Grade 3-4 toxicities are acute reversible Tm peaking at day 3-5 (52%), N (39.5%) and T (10.5%). Febrile N occurred in 2 cycles (5%). All 11 pts are evaluable for antitumor activity. Two PR (1 ongoing), 2 MR (2 ongoing) and 3 SD (lasting > 4 months) were observed. Among the 2 osteosarcomas, there was 1 PR and 1 MR. ET-743 is a promising new agent for heavily pre-treated refractory OS and STS. Based on this experience, a phase II program is ongoing, assessing the 1500µg/m²/24-hours CI schedule in such pts.

Please type

Presenting author

DELALOGUE

Institute / Company

Hop. Paul. Brousse

Department

ESMSIT

Address

12.14 Av Paul Vaillant

Postal code & City

94 800. Villetta F

Country code & Country

FRANCE

Telephone (International)

0331 4559 3631

Telefax (International)

331 45 59 37 37

e-mail address

Category (tick only one)

- ☐ ORAL preferred
☐ POSTER preferred
☒ NO PREFERENCE

Topics proposed for Proliferated Papers sessions.

Please tick ONE box which refers to the main subject of the abstract.

ECCO 10 Basic science/medicine programme

- | | | |
|--|---|---|
| <input type="checkbox"/> Biotherapy - gene therapy - vaccination | <input type="checkbox"/> Clinical pharmacology/Phase I | <input type="checkbox"/> Other gastro-intestinal tumours |
| <input type="checkbox"/> Bone marrow and stem cell supported therapies | <input type="checkbox"/> Colorectal cancer | <input type="checkbox"/> Other gynaecological tumours |
| <input type="checkbox"/> Breast cancer, clinical management - advanced disease | <input type="checkbox"/> Communication-Information and psychosocial aspects of oncology | <input type="checkbox"/> Ovarian tumours |
| <input type="checkbox"/> Breast cancer, clinical management - early disease | <input type="checkbox"/> Drug resistance and pre-clinical drug development | <input type="checkbox"/> Palliative and supportive care |
| <input type="checkbox"/> Breast cancer, genetics and biology | <input type="checkbox"/> Endocrine tumours | <input type="checkbox"/> Prevention of treatment related side effects |
| <input type="checkbox"/> Breast cancer, pathology and predictive factors | <input type="checkbox"/> Epidemiology and public health | <input type="checkbox"/> Prostate cancer |
| <input type="checkbox"/> Cancer cell biology and angiogenesis | <input type="checkbox"/> Head and neck cancer | <input type="checkbox"/> Radiobiology |
| <input type="checkbox"/> Cancer genetics | <input type="checkbox"/> Hodgkin's disease | <input type="checkbox"/> Radiotherapy techniques |
| <input type="checkbox"/> Cancer in children | <input type="checkbox"/> Leukaemia | <input checked="" type="checkbox"/> Soft tissue and bone tumours |
| | <input type="checkbox"/> Lung cancer | <input type="checkbox"/> Soluble tumour markers |
| | <input type="checkbox"/> Melanoma | <input type="checkbox"/> Testicular, renal and bladder cancer |
| | <input type="checkbox"/> Nervous system tumours | |
| | <input type="checkbox"/> Non-Hodgkin's lymphoma | <input type="checkbox"/> Miscellaneous |

ECCO 10 Nursing programme

- | | | |
|--|--|---|
| <input type="checkbox"/> Advancing cancer nursing practice | <input type="checkbox"/> Implementing research in cancer nursing | <input type="checkbox"/> State of the art in symptom management |
| <input type="checkbox"/> Children and young people with cancer | <input type="checkbox"/> Innovations in cancer nursing | <input type="checkbox"/> The challenge: moving cancer nursing forward |
| <input type="checkbox"/> Good clinical practice | <input type="checkbox"/> Research in progress | |

Key numbers

Please categorise your abstract by writing up to a maximum of three numbers corresponding to the list of keywords for subject indexing on page D of this form.

3.43 5.912 3.41



Publication Year: 1999

725

② A Phase I and Pharmacokinetic Trial of Ecteinascidin- 743 (ET- 743) Administered as a 72 Hour Continuous Infusion. *David P. Ryan, Jeffrey G. Supko, Joseph P. Eder, H. Lu, Bruce Chabner, Kristin Roper, Paul Baccala, Jill Bonerfant, Glenn Faircloth, C. Guzman, Jose Jimeno, Jeffrey W. Clark. Pharma Mar, S.A., Madrid, Spain.*

ET-743 is a tetrahydroisoquinoline alkaloid that binds to the minor groove of DNA. Since preclinical studies showed enhancement of tumor growth inhibition with prolongation of exposure, a phase I study of ET-743 administered as a 72 hour i.v. infusion every 21 days was initiated. 15 patients with metastatic solid tumors were enrolled: 9 men, 6 women; median age=52 years; 15/15 with ECOG performance status ≤ 1 ; 4/15 had > 2 prior regimens. The dose has been escalated from 600 mg/m² to the apparent maximum tolerated dose (MTD) of 1200 mg/m². Grade 3 transaminitis was not defined as a dose limiting toxicity (DLT). There were no DLTs among the 6 patients entered at the first two dose levels, but 2 patients on dose level 2 had grade 3 transaminitis. At dose level 3, 9 patients have received 15 cycles of ET-743. 2 patients had grade 4 and 5 patients had grade 3 transaminitis. AST/ALT levels increased on days 3-5, peaked on days 7-9, and returned to baseline by day 21. 1 patient at dose level 3 experienced grade 4 rhabdomyolysis, grade 4 neutropenia, grade 3 thrombocytopenia and acute renal failure during the 2nd cycle of therapy. Another patient at dose level 3 had grade 3 neutropenia. ET-743 plasma profiles were biphasic with a mean biological half-life of 59.9 ± 33.4 hr. Mean values of the total body clearance (CL), peak plasma concentration (C_{max}) and area under the curve (AUC) are summarized below.

Dose Level ($\mu\text{g}/\text{m}^2/72\text{hr}$)	CL (l/h/m ²)	C _{max} ($\mu\text{g}/\text{ml}$)	AUC (ng ^h /m ²)	Patients with DLT
1.600	29.4	283	12.0	0/3
2.900	35.7	581	24.7	0/3
3.1200	14.1	908	42.7	3/9

Activity was assessed by CT and PET scans before treatment and after every 2 cycles of therapy, as well as PET scan during week 2 of cycle 1. There was evidence of activity in 2 patients at dose level 3. A patient with mesothelioma showed a response by PET and CT scans that has not yet met criteria for PR. A patient with choroidal melanoma also showed reduced fluorodeoxyglucose uptake by PET scan after one cycle of therapy. Further refinement of the MTD and continued assessment of patients is ongoing.



© Copyright 1999 American Society of Clinical Oncology

1999 ASCO OFFICIAL ABSTRACT FORM

ONLY OFFICIAL 1999 ABSTRACT FORMS WILL BE ACCEPTED. DEADLINE FOR RECEIPT OF PAPER SUBMISSION ABSTRACTS IS DECEMBER 3, 1998. THE ELECTRONIC SUBMISSION PROGRAM GENERATES AN ELECTRONIC OFFICIAL ABSTRACT FORM.

Type abstract below using a 10-point typeface. It is recommended to limit abstract text to 300 words excluding abstract title, authors' names and affiliations.

3
FINAL RESULTS OF A PHASE I STUDY OF ECTEINASCIDIN-743 (ET-743) 24 HOURS (h) CONTINUOUS INFUSION (CI) IN ADVANCED SOLID TUMORS (AST) PATIENTS (pts). B. Cvitkovic¹, M. Riofrio¹, P. Goldwasser¹, S. Delalogue¹, A. Taamnia¹, J. Beljann¹, M. Jimeno¹, B. McKranz¹, C. Guzman¹, B. Brain¹, J.L. Misser¹. ¹Hop P. Brousse, Villejuif, France; ²The Netherlands Cancer Institute; ³Pharma Mar S.A., Spain; ⁴Centre R. Huguenin, Saint-cloud, France.

ET-743 is a novel minor groove DNA binding agent specific to guanine-cytosine rich regions with activity in murine tumor models and human cancer xenografts. Bone marrow and hepatic toxicities were dose limiting in animals. The results of phase I study with ET-743 CI 24 h given every 3 weeks, in AST pts are presented. Between 5/96 and 11/98, 49 pts received a total of 148 cycles (cy) over 9 dose levels (DL) (50-1800 µg/m²), median number of cy/pts = 2 (1-8). Median age 59 years (range 19-75) F/M = 28/21, median ECOG PS 1 (1-2). Tumor types: colorectal (12), sarcoma (11), breast (7), ovary (6), renal (3), bladder (2), gastric (2), ACUP (2), larynx (1), melanoma (1), 2 pts had both sarcoma and breast cancer. Acute nausea/vomiting (grade 2) were seen from the 600 µg/m² DL. Emesis was easily controlled. Reversible transaminases elevation peaking at days 3-7, back to baseline by day 14 occurred at the highest DL and was never a Dose Limiting Toxicity (DLT). The Maximal Tolerated Dose was 1800 µg/m², with neutropenia and thrombopenia being the DLTs. The Recommended Dose for phase II studies is 1500 µg/m². The table below summarizes the severe toxicities (NCI-CTC) by pts and cy observed at the 4 highest DLs:

DL	p/cy	Neutropenia		Thrombopenia		Transaminases	
		gr 3	gr 4	gr 3	gr 4	gr 3	gr 4
900	3/8	-	-	-	-	1/1	-
1200	5/19	-	-	-	-	2/2	-
1500	22/56	3/11	3/12	4/5	2/2	6/18	5/5
1800	4/16	-/5	1/10	-/1	2/3	1/4	2/2

One partial response (PR) was seen in pt with metastatic breast cancer refractory to anthracycline and docetaxel, another PR was observed in a heavily pretreated pt with metastatic osteosarcoma, with several minor and biological responses also seen in breast, sarcoma and colon, all in pts receiving doses ≥ 1200 µg/m². Phase II trials with ET-743 are warranted. Since treatment is ongoing in 6 pts, final results with all evaluable cy will be presented. PK/PD relationships are presented elsewhere.

2. Presentation Preference (check one box only)

- ☒ Slide or poster
☐ Poster only

3. IMPORTANT OPTION: If abstract is not selected for presentation, check this box for ASCO to withdraw your paper from publication in the Program/Proceedings.

4. Insert the code letters of the most appropriate category for your abstract. Please note that the ASCO Program Committee has the authority to re-categorize your abstract.

P.T.T.

5. ☐ For Merit Award consideration, check this box to certify that as the Presenter and the First Author, I am a fellow-in-training, resident, or medical student, and will be at the May 1999 ASCO meeting. A letter from my Training Director and a 2 page NIH bio sketch are attached.

6. Abstract SPONSOR: By signing below I certify that the information on this form is correct and its major contents have never been nor will be published before the 1999 ASCO Meeting. I also certify that this is the only 1999 ASCO abstract I am sponsoring.

Cvitkovic, Esteban

Printed Sponsor Name

Sponsor Signature

33(i) 45154045

Sponsor Fax Number

7. As an ASCO Associate Member, Presenter, and Sponsor of this abstract, the signature of my Program Director follows:

Program Director Signature

8. Abstract form must be accompanied by a completed Disclosure Declaration Form, which is on the reverse side of this abstract form. Please refer to attached Disclosure information. This form must be signed by the First Author on behalf of all co-authors.

- ☐ By checking this box, I hereby grant permission to ASCO to audio/record my voice and presentation for later resale.

1. First Author/Presenter Information (please type):

Cvitkovic

Surname/Last Name

ESTEBAN

First Name

MD

Degree/Suffix

S.M.S.T. Hopital Paul Brousse

Institution

12-14 Av. P. Brousse, Villejuif 94804 France

Address

33145154045

Telephone number

33145154045

Fax Number

e.cvitkovic@withamr-ac.fr

E-mail Address

Signature

By signature above, on behalf of all co-authors of this abstract, I hereby transfer my copyright to the American Society of Clinical Oncology.

Novel therapeutics and pharmacology

after radiotherapy, for a complete remission rate of 46% (6/18). The median duration of response was 10 months. The median survival of the entire patients population was 9 months with 33% survival rates at 1 year. The patient with AAO is free of disease at 82 months from the beginning of chemotherapy. Vomiting grade 3, hematologic toxicity grade 4 in one patient and grade 3 in two patients were the major complications due to chemotherapy, while nephrotoxicity and neurotoxicity were usually mild.

Conclusion: Our sequential chemo-radiotherapy regimen appears to have significant activity in adults with newly diagnosed high-grade gliomas.

636P AE-941 (Neovastat), an inhibitor of angiogenesis: Phase VII lung cancer clinical trial results

M. Rivani¹, J. Letreille², P. Falardeau¹, É. Dupont¹, ¹Alema Laboratories Inc., Ste-Foy, G1N 4A8, ²Centre Hospitalier de l'Université de Montréal, H2W 1T8, Canada

Introduction: AE-941 is a complex derived from cartilage that has shown both antiangiogenic and antimetastatic activities. Oral administration of AE-941 (125 mg/kg) resulted in approximately 50-70% reduction in the number of lung metastases using the Lewis Lung Carcinoma mouse model. No signs of toxicity were observed.

Methods: AE-941 is currently in Phase VII clinical trials in Canada and in the US for the treatment of lung, prostate and breast cancers. Patients were administered escalating doses (4) of AE-941 for 12 weeks. Tolerability and clinical benefits (tumor assessment, ECOG, body weight and analgesic consumption combined) were evaluated.

Results: Results obtained from 25 assessable patients of the Phase VI trial for lung cancer show a trend in favor of a dose/response effect of patients' clinical benefits. Doses ranging between approximately 10 to 80 mg/kg were administered orally, including the Canadian Special Access Program that started in July 1996 and the ongoing Phase VII clinical trials, approximately three hundred and thirty (330) patients have been exposed to AE-941 for up to 20 months without reporting any serious adverse events definitively associated with it.

Conclusions: Oral administration of AE-941 demonstrates a favorable safety profile and show a positive trend in favor of a dose/response improvement in clinical parameters. Complete results of Phase II lung and Phase I breast and prostate trials will be available Q3-98.

637P In vitro cytotoxicity of Tomudex (TOM) in combination with 5-Fluorouracil (5-FU) and levofolinic acid (LFA) in head and neck and colon cancer cell lines

A. Budillon, D. Barbarulo, E. Di Gennaro, C. Manzo, G. Comella, F. Caponigro, Istituto Nazionale Tumori G. Pascale, Napoli, Italy

Tomudex is a pure thymidylate synthase inhibitor, with clinical activity in colorectal cancer and in other solid tumors. TOM has recently been reported to down-regulate the activity of dihydropyrimidine dehydrogenase (DPD), and this implies a potential role for TOM in combination with 5-FU.

We have evaluated the cytotoxicity of TOM, 5-FU and LFA, when used in several different schedules in three colon cancer cell lines, (LOVO, GEO and SW620) and in one oral epidermoid carcinoma cell line (KB), using the SRB colorimetric assay.

LFA 5 μ M alone had no effect on cell proliferation, while in combination with 5-FU it reduced by about 50% 5-FU IC50 in all tested cell lines, as expected. If 5-FU was added simultaneously to TOM, a slightly additive effect was observed. When LFA, alone or in combination with 5-FU, was added simultaneously to TOM, it significantly inhibited TOM-induced cytotoxicity by increasing TOM IC50 up to 30 fold. The same effect was observed if cells were treated with LFA alone or in combination with 5-FU followed 24 hrs later by TOM. In this case TOM IC50 was increased up to 10 fold. When 5-FU alone was followed 24 hours later by TOM, an additive effect was observed. Interestingly, if cells were exposed for 24 hours to TOM and then to 5-FU + LFA, a clear synergism was observed in all tested cell lines, while only an additive effect was shown when 5-FU alone was added, thus indicating an important role for LFA in this schedule-dependent synergistic effect.

In conclusion, our preliminary in vitro studies suggest that LFA does not interfere with TOM cytotoxicity if a 24 hour interval elapses between the two drugs. In addition, this study also indicates that the combination of TOM followed 24 hours later by LFA+5FU is a worth pursuing approach for clinical investigation. Finally, we are currently measuring DPD activity in all tested cell lines in order to find out a possible correlation with in vitro synergistic effect.

638P Resistance to Gemcitabine (GEM) in a Fas-Ilgand (FasL)-resistant cell line is not dependent on the Fas/FasL (CD95/CD95L) system

M. Melli^{1,2}, M. Tolomeo³, N. D'Alessandro³, S. Grimaudo³, G. Ruberti¹, G. Papotti¹, L. Rassa¹, L. Dusanchez², ¹Institute of Oncology, ²Institute of Pharmacology, ³Chair of Hematology, University of Palermo, ⁴Institute of Cell Biology, CNR Rome, Italy

Introduction: The T-cell lymphoma HUT78B1 cells were selected by exposure

to a Fas-agonistic Ab and, in contrast to the parental HUT78, are resistant to Fas-mediated apoptosis owing to the expression of both a wild-type and a truncated Fas receptor. HUT78B1 retain sensitivity to apoptosis from various anticancer drugs, but are resistant to the cytidine analog GEM.

Methods and results: Cytotoxicity was evaluated by vitality assay and apoptosis by flow cytometry and fluorescence microscopy. In comparison with HUT78, HUT78B1 exhibited a high (about 100-fold) resistance to the cytotoxic and apoptotic effects of GEM. They were moderately cross-resistant to cytarabine, but retained sensitivity to fludarabine or hydroxyurea. To clarify whether the Fas/FasL system plays a role in the cellular response to GEM, we evaluated the effects of GEM in HUT78 after pretreatment with FasL (NOK1, NOK2) or Fas (ZB4, DX2) blocking antibodies or the inhibitor of caspase 8 ZVAD-cmk. Overall, we did not observe any clearcut effect of such blocking reagents on GEM-induced apoptosis and cytotoxicity. In spite of an increase in FasL levels after 4 or 8 h of exposure to GEM, as shown by Western blotting assay. However, the apoptotic effects of GEM were suppressed by Z-VAD, a wide spectrum inhibitor of caspases. Finally, HUT78B1 accumulated about 10-fold less 3H-GEM than HUT78.

Conclusions: The antitumor effects of GEM on HUT78 cells do not correlate to the Fas/FasL pathway, whereas they seem to be dependent on the caspase cascade. GEM accumulation by the cells might account for the response to GEM in this model. The possible interactions between the Fas/FasL system and chemotherapeutic agents deserve further investigations and might have relevance to cancer therapy. Supported by Eli Lilly.

639P Ecteinascidin-743 (ET-743) 24 hours continuous infusion (CI): Clinical and pharmacokinetic phase I study progressive report

M. Rigoletto¹, A. Tasmann¹, B. Mckranter¹, F. Goldwasser¹, J. Jimeno², C. Jasmin¹, J.L. Missel¹, E. Cvitkovic¹, ¹FSMST, Hôpital Paul Brousse, Villejuif, France; ²Pharma Mar, Madrid, Spain

Introduction: ET-743, a tetrahydroisoquinoline alkaloid isolated from the Ecteinascidia Turbinate, a minor groove DNA binding agent specific for the guanine rich regions, with potent activity in murine tumor models and in human lines in vitro and in vivo. Bone marrow and liver function toxicity were shown in preclinical studies. A phase I study with ET-743 LV, 24 hours C.I. every 21 days is ongoing, in solid advanced stages tumors.

Methods: Since May 1996, 31 pts were treated over 9 dose levels (DL) from 50 to 1600 μ g/m². Median number of cycles/pts: 2 (1-6), median age: 55 (26-74). FM: 18/13, ECOG PS: 1 (0-2). Tumor types: colo-rectum (7), ovary (4), sarcoma (7), renal (3), breast (4), bladder (2), larynx (1), gastric (2) and ACUP (1), all refractory to standard chemotherapy. Nausea/vomiting (grade 2) and reversible (4-6 days) transaminase elevation starting 2-4 days after treatment were seen from 600 μ g/m² DL. This toxicity is self limiting (resolved by day 7-10). Maximal transaminase (ASAT-ALAT) elevation, and neutropenia, at the five highest DL is shown below (NCIC-CTO)

Dose level μ g/m ²	Pst/Oy	Neutropenia		Transaminases	
		Grade 0-2	Grade 3-4	Grade 0-2	Grade 3-4
500	3/6	2/6	-	2/6	-
800	3/6	2/6	-	2/7	1/1
1200	5/19	5/19	-	3/17	2/2
1600	4/18	1/8	3/7	1/8	3/7
1800	4/7	2/2	2/3	1/2	3/5

Conclusion: The incidence of reversible grade 4 transaminases and frequency of grade 4 neutropenia suggest that MTD is close to 1800 μ g/m²

640P Optimization of tumor suppressor genes delivery using original cationic lipids in malignant mesothelioma cells

S. Piperno-Neumann^{1,2}, X.A. Cao¹, R. Couden¹, J.L. Bresau², M.C. Jaurand¹, E. TAILLANDIER¹, ¹Laboratoire de Spectrométrie Moléculaire, Université Paris XIII, Bobigny, France; ²Service d'Oncologie Médicale CHU Avicenne, Bobigny, France

Human malignant mesothelioma (MM) displays chromosomal abnormalities, particularly homozygous deletions of the p16 tumor suppressor gene.

In attempt to replace altered genes in MM cell lines in culture and in nude mice xenograft, we developed a non viral gene delivery technique, using original synthetic cationic liposomes V14 and V5, and a DNA compacting agent spermine. Transfection using naked DNA or commercialized cationic lipids is inefficient in MM cells. Cell lines were established from the MM of patients in accordance with pathological criteria, and prior to therapy.

The first step was to test the ability of different carriers: DOTAP, lipofectine, and original V5 and V14. Therefore, we studied the β galactosidase (β gal) gene expression in 3 human MM cell lines in culture (RAV, FER, BLA), after transfection of a β gal reporter gene (pCMV β CLONTECH) complexed to lipids. 2.10⁵ cells were transfected with 0.5 to 9 μ g of pCMV β alone, condensed with spermine, then complexed to cationic lipids. The β gal activity was measured by chemoluminescence (GloMax³ TROPIC) 48 hours after transfection. The